IL-4 enhances expression and function of surface IgM in CLL cells by Aguilar-Hernandez, Maria M. et al.
1 | P a g e  
 
IL-4 enhances expression and function of surface IgM in CLL cells  
Maria M. Aguilar-Hernandez1#, Matthew D. Blunt1#, Rachel Dobson1#, Alison Yeomans1, Stephen 
Thirdborough1, Marta Larrayoz1, Lindsay D Smith1, Adam Linley1, Jonathan C Strefford1, Andrew 
Davies2, Peter MW Johnson2, Natalia Savelyeva1, Mark Cragg4, Francesco Forconi1,3, Graham Packham1, 
Freda K Stevenson1, and Andrew J. Steele1 
1Cancer Research UK Centre, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, 
Southampton, UK. 
2Medical Oncology, University, Hospital Southampton National Health Service Trust, Southampton, 
United Kingdom 
3Haematology Department, University Hospital Southampton National Health Service Trust, 
Southampton, United Kingdom. 
4Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, 
Southampton, UK. 
 
# these authors contributed equally 
 
Corresponding author: Dr A Steele, Cancer Sciences Unit, Somers Building (MP824), Southampton 
General Hospital, Tremona Rd, Southampton SO16 6YD, UK 
e-mail: a.steele@soton.ac.uk 
Phone:  (44) 238 120 5170 
Fax: (44) 238 120 5152 
Text word count: 3821 
Number of figures - 7  
 
Number of Supplementary figures - 4 
Number of Supplementary Tables - 1 
Abstract word count: words 240 
Keywords; CLL; Interleukin 4; B-cell receptor; JAK3; STAT6, sIgM 
 
Running title: IL-4 regulates the B cell receptor  
 
 
 
2 | P a g e  
 
Abstract  
Kinase-inhibitors targeting the B-cell receptor (BCR) are now prominent in the treatment of CLL. We 
have focused here on IL-4, a cytokine which protects normal and malignant B cells from apoptosis, 
and increases surface (s)IgM expression on murine splenic B cells. First we have demonstrated that IL-
4 treatment increased sIgM expression in vitro on peripheral blood B cells obtained from healthy 
individuals.  In CLL, IL-4 target genes are overexpressed in cells purified from the lymph nodes of 
patients compared to cells derived from matched blood and bone marrow samples.  As for normal B 
cells, IL-4 increased sIgM expression on CLL cells in vitro, especially in samples expressing unmutated 
V-genes (U-CLL). IL-4-induced sIgM expression was associated with increased receptor signalling 
activity, measured by anti-IgM-induced calcium mobilisation, and with increased expression of CD79B 
mRNA and protein, and the “mature” glycoform of sIgM. Importantly, the ability of the BCR-associated 
kinase inhibitors idelalisib and ibrutinib, approved for treatment of CLL and other B-cell malignancies, 
to inhibit anti-IgM-induced signalling was reduced following IL-4 pre-treatment in samples from the 
majority of patients. In contrast to stimulatory effects on sIgM, IL-4 decreased CXCR4 and CXCR5 
expression. Therefore CLL cells, particularly within the progressive U-CLL subset, may harness the 
ability of IL-4 to promote BCR signalling and B-cell retention within lymph nodes. Effects of IL-4 were 
mediated via JAK3/STAT6 and we propose a potential role for JAK inhibitors in combination with BCR-
kinase inhibitors for the treatment of CLL. 
 
 
Key Points  
 IL-4 treatment augments sIgM expression and subsequent downstream signalling in a 
JAK3/STAT6 dependent manner within CLL samples 
 IL-4 exposure partially opposes the activity of BTK or PI3K inhibitors on sIgM-mediated 
signalling. 
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Introduction 
The finding that clinical outcome is linked to the immunoglobulin mutational status in chronic 
lymphocytic leukaemia (CLL) focused attention on the role of the B cell receptor (BCR) in this disease.1-
3 The clinical success of the BTK inhibitor ibrutinib and the PI3K inhibitor idelalisib has further 
highlighted a key role of the BCR. Interestingly, treatment-naive M-CLL cases tend to respond more 
slowly to ibrutinib and to have fewer complete remissions than U-CLL.4 This difference could reflect 
the fact that, although sIgM expression and signal capacity is down-modulated in all cases compared 
to normal B cells, U-CLL samples tend to retain higher levels of surface IgM (sIgM) expression and 
signalling capacity compared to M-CLL5-8. Although the drivers of BCR signalling in CLL are unknown, 
in vitro investigations suggest microbial-derived antigens, autoantigens and autonomous signals could 
be involved.9-12 Antigen/autoantigen binding to the BCR results in phosphorylation of CD79A and 
CD79B by Src family kinases13, leading to assembly and activation of the signalosome which comprises 
proteins essential for BCR-induced signal transduction including BTK and PI3K3. sIgM expression 
appears to be the main determinant of variable sIgM-signalling capacity5. However, the specific factors 
that may influence sIgM expression in CLL cells are not known. 
 
Binding of IL-4 to the IL-4 receptor (IL-4R) on B cells results in JAK1/3-mediated phosphorylation of 
STAT6 (pSTAT6).14 pSTAT6 dimerizes and translocates to the nucleus where it induces expression of 
multiple target proteins (including Bcl-2 family members, Bcl-XL and Mcl-1,15 MHCII and CD23) and 
promotes immunoglobulin class switching.16,17 Moreover, IL-4 is also important for B-cell proliferation 
and differentiation, and the formation of the germinal centers in mice.18-20 In CLL samples, IL-4 
suppresses basal and chemotherapy-induced apoptosis15,21-23, probably via increased expression of 
anti-apoptotic proteins15.  
 
IL-4 is one of the cytokines classically synthesised by CLL T cells24,25. Importantly, CLL patients with 
progressive disease have been reported to have a significantly greater number of T cells that 
spontaneously produced IL-4 compared to patients with non-progressive disease or healthy 
individuals.26  CLL cells themselves express a significantly greater number of IL-4 receptors (IL-4R) 
compared to normal B cells,27,28 and this is consistent with increased pSTAT6 expression in CLL 
samples,29 consequent to the augmentation of STAT6-dependent signalling pathways. Furthermore, 
in an adoptive transfer model of CLL, T cells were essential for tumour engraftment.30 Together these 
data suggest a role for T cells and perhaps IL-4 in CLL biology. 
 
IL-4 has previously been shown to induce sIgM expression and signalling capacity in murine splenic B 
cells31,32.   An early study on the effects of IL-4 on αIgM-induced proliferation using six CLL samples 
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showed a heterogeneous response which could have reflected changes in levels of sIgM, but this was 
prior to the description of the two subsets of disease33.  Here, we show that IL-4 also augments sIgM 
expression and signalling in the majority of CLL samples. Importantly, we show that IL-4 partially 
overcomes ibrutinib- or idelalisib-mediated inhibition of sIgM signalling. Stimulatory effects of IL-4 
were reversed using JAK3 or STAT6 inhibitors. These results suggest that the ability of IL-4 to enhance 
effects of antigen in tissues may have been captured by CLL cells to promote tumorigenesis. 
 
Methods 
Patient and normal donor samples 
Diagnosis of CLL was according to the IWCLL-NCI 2008 criteria.34 Seventy-four CLL cases were studied 
following informed written consent in accordance with ethics committee approvals under the 
declaration of Helsinki (Supplementary Table 1). Procedures for the isolation of malignant cells and 
the determination of their purity have been described previously.5 All isolates contained >90% 
CD19+CD5+ cells. Normal donor peripheral blood mononuclear cells (PBMC) were obtained from 
anonymized leukocyte cones from the National Blood Service (Southampton, UK) following ethical 
approval. PBMCs were obtained using density gradient centrifugation (Lymphoprep), resuspended in 
cryopreservation medium (90% fetal calf serum, 10% DMSO) and frozen in liquid nitrogen prior to use 
in order to replicate our procedure with CLL PBMCs.  
 
Cell culture and protein extraction 
CLL cells were cultured and protein extracted as previously described.15,35 Soluble anti-IgM F(ab’)2 was 
used at 20µg/ml5, bead bound immobilised anti-IgM F(ab’)2 was added at 2:1 ratio, bead:CLL cell as 
previously described.36 
 
Flow Cytometry 
Cells were labelled for 30 minutes at 4°C with antibodies conjugated to various fluorochromes. Data 
were acquired on a BD FACSCanto II. All mean fluorescence intensity (MFI) and percent positive 
staining were measured relative to an isotype control. Detection of intracellular calcium was 
quantitated following incubation with 4µM Fluo3-AM (Life Technologies, UK) and 0.02% (vol/vol) 
Pluronic F-127 (Sigma, UK). Results are presented as; % responding cells = ([Maximal Peak height 
following anti-IgM treatment – mean of unstimulated samples] / % CD19+ve cells) x 100.   1µM 
Ionomycin (Sigma) was added as a positive control. Analysis was performed using Flowjo v10. 
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Biotinylation of cell-surface proteins 
Biotinylation, isolation of cell surface proteins and digestion using endoglycosidase H (EndoH) was 
performed as previously described.37  
 
Gel electrophoresis and Immunoblotting 
Proteins were separated on 12% polyacrylamide gels (Thermo Fisher, UK), transferred to nitrocellulose 
membranes (GE Healthcare, Buckinghamshire, UK) and probed with anti-HSC70 (Santa Cruz, CA), anti-
actin (Sigma Aldrich, Poole, UK) and anti-Bcl-2 (Dako, Glostrup, Denmark) as loading controls. Anti-
CD79B was from Abcam. All other antibodies were from Cell Signaling Technology (Hitchin, UK). Bands 
were detected by incubation with HRP-linked secondary antibodies (Dako), enhanced 
chemiluminescence reagents (Thermo Scientific, Rockford, IL) and visualised using the ChemiDoc-It 
imaging system (UVP, UK). Band intensities were quantified using ImageJ and normalised to HSC70, 
Actin or Bcl-2 as indicated. 
 
Results 
IL-4 enhances sIgM expression in B cells from healthy human donors 
Previous studies have demonstrated that IL-4 enhances sIgM expression in murine B cells.31,32 Before 
initiating studies in CLL samples, we investigated the effects of IL-4 in normal human B cells. PBMCs 
were obtained from 5 individual donors and sIgM expression analysed on the naive (CD19+CD27-) and 
memory (IgG-CD19+CD27+) B-cell populations using flow cytometry (Figure 1A). PBMCs were treated 
for 24h with IL-4 or the vehicle control (RPMI1640 supplemented with 10% fetal calf serum and 
antibiotics) prior to evaluation of sIgM levels. IgM-memory B-cells expressed higher levels of sIgM 
compared to naive B-cells as previously demonstrated38 (Figure 1B). The IL-4-induced fold-increase in 
naive cells (mean 2.7-fold) was significantly greater than that of IgM-memory cells (mean 1.5-fold; 
p=0.0012). Modulation of sIgM was not secondary to effects of IL-4 on cell death since the proportion 
of dead cells was low (<5%) and not effected by IL-4 in either B-cell subset (data not shown). 
  
IL-4 target gene expression in CLL cells in vivo 
We performed gene-set enrichment analysis (GSEA)39 to investigate potential effects of IL-4 in CLL 
patients in vivo. We identified a set of IL-4-regulated genes from a previously published study of CLL 
cells following treatment in vitro with IL-440, and investigated whether these specific target genes were 
enriched in the transcriptional profiles of CLL cells purified from lymph node (LN) compared to 
matched blood and bone marrow.41 GSEA revealed a significant enrichment of expression of IL-4-
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target genes in LN-derived CLL cells, compared to CLL cells isolated from the other tissues 
(Supplementary Figure 1), consistent with IL-4-dependent transcriptional activity in CLL LN in vivo. 
 
IL-4 enhances expression of sIgM on CLL cells. 
We investigated the effects of IL-4 on expression of sIgM on CLL cells isolated from the blood of 
patients. In our initial analysis, CLL samples were treated with or without IL-4 (10 ng/ml), and sIgM 
expression quantified by flow cytometry at the start of the experiment, and at various times up to 72 
hours. A representative sample is shown (Figure 2A) and summarised data are presented (Figure 2B). 
As previously demonstrated,5 incubation in vitro without IL-4 was associated with a modest increase 
in sIgM expression, which was most evident at 72 hours. Compared to the vehicle control, IL-4 
increased sIgM expression at all time points. Due to potential confounding effects of apoptosis at later 
time points (48-72h), we extended the analysis by investigating effects of IL-4 on sIgM expression at 
24 hours in additional samples. In this extended analysis (n=33 samples), IL-4 increased overall sIgM 
expression (Figure 2C). However, there was variability in response between individual samples. In 
contrast to sIgM, IL-4 treatment on the whole did not significantly alter expression of sIgD, although a 
small subset with sIgD MFI levels >40 (in grey) increased their receptor expression in response to IL-4 
(Figure 2D-F). We investigated whether the variation in effects of IL-4 on sIgM expression at 24 hours 
correlated with CLL prognostic markers. IL-4-increased sIgM expression was significantly greater in U-
CLL compared to M-CLL (p=.0016) (Figure 2G) and in ZAP70+ compare to ZAP70- samples (p=.016) 
(Figure 2H). In contrast, IL-4 effects were not significantly different between CD38+ and CD38- samples 
(Figure 2I). 
 
Effects of IL-4 on sIgM expression are mediated via JAK/STAT signalling 
We investigated effects of IL-4 on JAK3-mediated pSTAT6. CLL cells were treated with varying 
concentrations of IL-4 (0.1–10 ng/ml) for 24 hours, and pSTAT6 quantified by immunoblotting. IL-4 
induced a dose-dependent increase in pSTAT6 with a maximal response detected at 
concentrations >1ng/ml (Figure 3A) and was paralleled by increased sIgM expression (Figure 3B), but 
not sIgD (Supplementary Figure 2A). We also investigated responses to additional cytokines, including 
IL-13 (a known inducer of pSTAT6)16, IL-2, IL-6, IL-8, IL-10, and IL-21. Only IL-4 increased pSTAT6 and 
sIgM expression (Figure 3C-D). The type II IL-4R which regulates IL-13 signalling, is generally the 
exclusive receptor expressed by non-hematopoietic cells, and may partially explain the lack of pSTAT6 
induced by IL-13.42,43 None of the cytokines altered expression of sIgD (Supplementary Figure 2B).  
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To directly investigate the role of JAK3/STAT6 signalling in IL-4-mediated sIgM induction, CLL cells were 
pre-treated for 1 hour with the JAK3 inhibitor tofacitinib (CP; 10M) or the STAT6 inhibitor AS1517499 
(AXON; 1M) and then incubated for an additional 23 hours in the presence or absence of IL-4 before 
analysis of sIgM expression. Inhibitor concentrations selected for these experiments were based on 
initial titration experiments to identify optimal inhibitory concentrations (Supplementary Figure 2C-
D). AS1517499 and Tofacitinib had no effect on sIgM expression when tested alone, but completely 
blocked the ability of IL-4 to enhance sIgM expression (Figure 3E). The inhibitors had no effects on CLL 
cell viability at times up to 24 hours (data not shown). Therefore, IL-4-induced increases in sIgM 
expression appear to be mediated via JAK/STAT signalling. 
 
Increased sIgM expression is associated with higher sIgM signalling capacity in IL-4-treated cells 
We investigated whether the ability of IL-4 to increase sIgM expression at 24 hours was associated 
with increased receptor function using intracellular calcium fluxes as a highly quantitative measure of 
signal responses5. IL-4 increased anti-IgM-induced calcium mobilisation, shown in a representative 
sample (Figure 4A) and summarised in a larger cohort (Figure 4B), and was accompanied by an 
increased ability to phosphorylate ERK (Supplementary Figure 2E & 2F). 64% of samples produced >1.2 
fold increase in calcium flux, 11% had a 1-1.2 fold change. No change or a small reduction <0.3 fold 
was observed in 24% of samples, however this was partially confounded due to a small proportion 
(4/9) of samples which were unable to increase calcium mobilisation further because they already 
produced a substantive signalling response (>50%) prior to IL-4 addition.  Overall, IL-4 treatment did 
not alter responses to anti-IgD (Figure 4C), however 4 samples with unmutated IGHV did increase >1.2 
fold. Similar to effects on sIgM expression, stimulatory effects of IL-4 on anti-IgM-induced calcium 
signalling were concentration-dependent (Figure 4D; Supplementary Figure 2G), with maximal 
response at concentrations >1ng/ml. Moreover, the JAK3 inhibitor tofacitinib also inhibited the 
stimulatory effects of IL-4 on sIgM signalling (Figure 4A).  
 
IL-4 increases CD79B expression 
We investigated the effects of IL-4 on expression of CD79A and CD79B, two consort molecules which 
are essential for sIgM expression and signalling44. β2 microglobulin and Bcl-2 were used to normalise 
loading for RNA and protein analysis respectively, since their expression did not change upon IL-4 
treatment.   IL-4 increased expression of CD79B at the RNA (Figure 5A) and total and surface protein 
(Figure 5B-C, Supplementary Figure 3A) at 24h. In contrast, IL-4 treatment resulted in a slight reduction 
in expression of CD79A RNA (Figure 5A) but with no discernible effects on protein expression (Figure 
5B). Similar to effects on sIgM expression, effects of IL-4 on CD79B were greater in U-CLL compared 
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to M-CLL samples (Figure 5D). However, no difference in IL-4R expression was observed between U-
CLL and M-CLL in a small cohort of CLL (Supplementary Figure 3B), indicating IL-4R expression does 
not explain the differential response between the CLL subsets.   
 
IL-4 increased expression of the “mature” sIgM glycoform  
Previous investigations by our group found that the µ-chain of sIgM in CLL cells exists in two forms 
with distinct N-glycosylation patterns; a mature (fully glycosylated) glycoform typical of normal B cells 
and an immature (high mannose) glycoform more characteristic of IgM in the ER, but found on the 
cell surface after BCR-mediated activation.37 Incubation of CLL cells in vitro led to a restoration in 
expression of the mature sIgM glycoform37. To investigate effects of IL-4, we analysed the expression 
and glycosylation of µ-chain using whole cell lysates and cell surface protein-enriched fractions, 
isolated by biotinylation and streptavidin capture. A representative sample is shown (Figure 5E) and 
summarised for 12 samples (Figure 5F). Although whole cell expression of µ-chain was not altered, IL-
4 significantly increased the relative abundance of the mature µ-chain glycoform on the cell surface 
(SP) as shown by increased expression of a more slowly migrating protein band (Figure 5E). In one case 
with pre-existing high levels of the mature glycoform, this was stable (Figure 5F). Incubation with 
endoglycosidase H to remove terminal mannose selectively removed glycans from the more rapidly 
migrating protein, confirmed that this glycoform contained high mannose (Figure 5E). Therefore, IL-4 
appears to enhance the ability of CLL cells to replace the immature sIgM glycoform with the fully 
glycosylated form typical of resting normal B cells, but without changes in overall µ-chain expression. 
 
 
 
Effect of IL-4 on apoptosis and on inhibition of sIgM signalling by ibrutinib and idelalisib 
IL-4 appears to protect against ibrutinib and idelalisib induced apoptosis45,46. Here we investigated 
whether IL-4 influenced the response of CLL cells to drug-induced inhibition of the BCR signalling 
pathway at concentrations in accordance with the literature45,46. CLL samples were treated with IL-4 
for 23h and then pre-treated with kinase inhibitors for 1h prior to anti-IgM induced calcium flux. A 
representative experiment is shown (Figure 6A-B), and the data summarised (Figure 6C-D (idelalisib 
(5µM) & ibrutinib (10µM) and Supplementary Figure 4A-B, (1µM idelalisib or ibrutinib)). The kinase 
inhibitors significantly reduced CLL viability at 48h (Supplementary Figure 4C) and anti-IgM-induced 
signalling in the absence of IL-4 at 1h. IL-4 treatment alone increased both CLL viability and anti-IgM-
induced calcium responses in the absence and in the presence of inhibitors. Clearly IL-4 has two effects 
on CLL cells: first in protection against apoptosis per se even in the presence of drugs, and second on 
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the upregulation of sIgM.  These may not be tightly linked however, since upregulation of sIgM did 
not appear to be linked to the level of viability (Supplementary Figure 4D).  IL-4 treatment had no 
impact on the expression of BTK or PI3Kδ at the mRNA or protein level indicating that the reduced 
sensitivity to idelalisib and ibrutinib was not due to reduction in expression of their target protein 
(data not shown). Therefore, IL-4 may reduce the inhibitory effects of BCR kinase inhibitors.  
 
The effect of IL-4 on other cell surface receptors  
We investigated whether IL-4 modulated expression of other receptors important for CLL cell 
behaviour. We initially focused on CXCR4 which is thought to play an important role in homing and 
retention of CLL cells in LNs47,48. CXCR4 is down-modulated on tissue-localised CLL cells41 (presumably 
due to ligand-induced receptor endocytosis) and we have shown that culture of CLL cells in vitro is 
associated with a recovery of CXCR4 expression49. We therefore investigated whether IL-4 modulated 
this natural recovery by incubating cells in the presence or absence of IL-4 and quantifying CXCR4 
expression by flow cytometry. A representative sample is shown (Figure 7A) and the data summarised 
(Figures 7B and C and Supplementary Figure 5A-C). As previously shown49, culture in vitro was 
associated with a substantial increase in CXCR4 which peaked at 24 hours. However, in contrast to 
effects on sIgM, IL-4 significantly reduced CXCR4 expression. Overall, IL-4 reduced CXCR4 expression 
by ~50% at 24 hours (Figure 7C) and by 72 hours CXCR4 expression was almost undetectable (Figure 
7B). Effects on CXCR4 were specific for IL-4 amongst tested cytokines (Figure 7D) and effectively 
blocked by JAK3 or STAT6 inhibition (Figure 7E). Consistent with reduced CXCR4 expression, IL-4 also 
reduced CXCL12-dependent CLL cell migration (Figure 7F). In a subset of CLL samples treated with IL-
4, we also investigated CXCR4 expression in CD19-CD5+ cells (T cells). In contrast to the CLL cells, IL-4 
treatment of CD19-CD5+ cells resulted in an increase in CXCR4 expression (Supplementary Figure 5C).  
This indicated that the effects of IL-4 may be cell specific. The reduction in CXCR4 protein levels in CLL 
cells was also transcriptionally regulated, since IL-4 also reduced CXCR4 mRNA levels (Supplementary 
Figure 5D). IL-4 also reduced expression of the related chemokine receptor CXCR5 (Supplementary 
Figure 5E-F). 
 
The modulatory effects of IL-4 were investigated on additional cell surface markers including CD19 
and the activation markers CD69, CD23 and CD71 which are generally over-expressed on CLL cells 
compared to normal donor B cells.50 Although CD19 and CD71 expression were unaltered, IL-4 
increased expression of CD69 and CD23 (Supplementary Figure 6A-D). These data indicate a 
considerable degree of selectivity amongst the receptor modulating effects of IL-4. 
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Discussion  
CLL appears to be a BCR-driven malignancy and the expression of sIgM and subsequent downstream 
signalling are involved in disease behaviour. Cases of U-CLL, a subset of poorer prognosis, generally 
express higher levels of sIgM and subsequently produce a stronger signal compared to M-CLL in 
response to anti-IgM.3,51 Clearly there is a potential for microenvironmental factors to influence BCR 
signaling and previous studies have shown that BAFF and CD40L promote sIgM-mediated signalling in 
CLL cells52.  In those studies, regulation appeared to involve an indirect potentiation of intracellular 
signal transduction via miRNA-155-mediated suppression of the inhibitory phosphatase SHIP152.  By 
contrast, IL-4 appears to promote sIgM signalling, at least in part, via direct upregulation of IgM 
expression at the cell surface. 
 
GSEA revealed a clear signature of IL-4-mediated transcription in the LN of CLL patients, compared to 
matched blood and bone marrow samples, indicating that IL-4 may be acting on the malignant cells in 
the LN tissue. The source of IL-4 remains unknown, but CD4+ T cells are detectable, and are likely to 
be involved24,53. TFH cells a known source of IL-4 are also increased in the blood of CLL patients and, 
although unambiguous identification in tissues remains difficult, T cells with features of TFH have been 
observed in CLL lymph nodes54. Interestingly, although circulating T cells from CLL patients have 
increased exhaustion markers and have impaired proliferation, cytotoxicity and synapse formation55,56 
they retain their capacity for cytokine production.56   
 
In terms of effects of IL-4 on CLL cells, we found that sIgM, but not sIgD expression, increased following 
IL-4 treatment in vitro.    Since there was no detectable increase in total cellular IgM following IL-4 
treatment, the increase in surface expression may be due to “shunting” of IgM from the endoplasmic 
reticulum (ER) to the cell surface.  The relative increase in the fully N-glycosylated glycoform is 
consistent with this.  Our data in CLL cells are similar to those described in mouse splenocytes where 
IL-4 promoted sIgM expression, leading to enhanced downstream signalling31,32,57. In normal mouse 
splenocytes, there was co-amplification of CD79A and CD79B, consort molecules for sIgM 
expression31, whereas in CLL, there was a clear accompanying increase in CD79B expression, which is 
consistent with the reports that CD79B limits BCR assembly in CLL58. However CD79A protein 
expression was more difficult to interpret due to the detection of multiple bands on the immunoblot 
caused by IL-4 induced glycosylation of this protein. It seems therefore that there may not be a defect 
in the ability of µ chains to undergo N-glycosylation and assembly with CD79A and CD79B in the ER of 
CLL cells58. Instead there appears to be regulation of the subsequent process of movement through 
the Golgi complex to the membrane, possibly via IL-4-mediated CD79B upregulation.  In contrast, 
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there was little effect of IL-4 on sIgD expression, consistent with the suggested reduced dependence 
on CD79A and CD79B59.    
 
Expression in CLL cells of several other receptors (CD19, CD71) did not significantly change following 
IL-4 pre-treatment, however two key receptors; CXCR4 and CXCR5 which are involved in cell migration 
into the lymph node were downregulated. In contrast, CXCR4 was upregulated in CD19-CD5+ cells (T-
cells). These results suggested a possible role by IL-4 in recruiting T cells to and retaining B cells within 
the lymph node. This is also consistent with previous reports where CXCR4 is upregulated by IL-4 in 
normal peripheral and cord blood T cells.60 Importantly these data indicated that in CLL the mechanism 
of IL-4 is both receptor- and cell type-dependent. The IL-4-mediated downregulation of CXCR4 
expression and function by CLL cells mirrors the effect of BCR stimulation on this receptor61,62 
suggesting that these influences may be acting together to locate cells to extrafollicular sites63 where 
enhanced IgM expression then increases antigen engagement and subsequent downstream signalling 
events. 
 
The effects of IL-4 appear to be common to all B cells, since both naive and memory B cells respond 
to IL-4 in a similar way to CLL cells, however naive CD27- B-cells responded to a greater extent than 
CD27+ memory B-cells, indicating that the effect of IL-4 may be dependent on the cell of origin. 
Therefore the higher level of response to IL-4 in U-CLL cases may simply reflect its origin from a naïve 
B cell49.  We propose that CLL cells may highjack the naturally occurring IL-4 signalling pathway to 
augment BCR signalling and promote B-cell proliferation and survival, especially within the U-CLL 
subset. 
 
In addition to effects of IL-4 on sIgM expression and function, we have also shown that this cytokine 
decreases  the inhibitory effects of idelalisib or ibrutinib on anti-IgM-induced signalling and protects 
against BCR-kinase inhibitor induced apoptosis. The presence of significant numbers of CD4+ T cells 
in proliferation centers53, accompanied by an IL-4 gene signature (above), might lead to an increase 
in expression of sIgM in non-mobilized tumor cells and therefore could protect a subpopulation from 
kinase inhibition. The greater effect on U-CLL suggests that CLL cells with more responsive” signaling 
via sIgM engagement6-8 may be more sensitive to IL-4.   However, the clinical observation of a 
reduced effect of inhibitors on disease load in M-CLL might be due to the greater proportion of 
anergic cells, which respond poorly to BCR signals and to IL-4, and would therefore persist during 
therapy51. Since IL-4 effects are mediated by the JAK3/STAT6 pathway, we are currently investigating 
whether JAK3 inhibition in combination with BCR kinase inhibitors is capable of promoting more 
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durable remissions in vivo in the Eµ-TCL1 mouse model. These data clearly indicate that cytokines 
operating within the tumour microenvironment enhance BCR signalling, reduce sensitivity to BCR-
kinase inhibitors and may have relevance for other B-cell malignancies.  
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Figure Legends 
Figure 1.  IL-4 enhances sIgM expression in B cells from healthy human donors 
(A) Depicts the gating strategy for determining the naive and memory B cells from normal donors and 
described in detail in the Supplementary methods. (B) PBMCs were extracted and treated with and 
without IL-4 (10ng/ml) for 24h. Using the gating strategy in (A) sIgM levels were quantitated by flow 
cytometry in the naive and memory B cell. Statistical significance was determined by a paired students 
T test where indicated (B). 
 
Figure 2. IL-4 enhances expression of sIgM, but not sIgD, on CLL cells 
Histogram of (A) sIgM and (D) sIgD expression on a representative CLL sample. Graph shows sIg 
expression at the start of the experiment (black dotted line), and at 24 hours in the presence (solid 
black line) or absence (dashed line) of IL-4 (10 ng/ml), respectively. Grey histogram = isotype control 
antibody. (B) and (E)  shows results (MFI minus isotype control) for cells treated with IL-4 or left 
untreated as a control (NA) for up to 72 hours. (C) and (F) shows all results expressed as Mean 
Fluorescent Intensity Ratios (MFIR) from samples analysed at 24 hours (C, n=33; F, n=29). (G-I) 
Correlation between the increase in sIgM ((sIgM MFI with IL-4) - (sIgM MFI without IL-4)) and 
prognostic markers. Samples are categorised according to (G) IGHV mutational status, (H) ZAP70 
expression and (I) CD38 expression. Mean fluorescent intensity (MFI). Error bars represent the 
standard error of the mean (SEM). Statistical significance was determined by either a paired (B, C, E 
and F) or unpaired (G-I) students T test or Wilcoxon matched pairs signed rank test. 
 
Figure 3. Effects of IL-4 on sIgM expression are mediated via JAK/STAT signalling 
CLL samples were treated with IL-4 (0.1-10 ng/ml) for 24 hours and (A) phosphorylated STAT6 (pSTAT6) 
and (B) sIgM expression analysed using immunoblotting and flow cytometry, respectively. (A) Shows 
a representative sample and (B) represents summarised data (n=6). (C,D) CLL cells were pre-treated 
with the indicated cytokines and (C) phosphorylated STAT6 (pSTAT6) (n=9) and (D) sIgM quantified by 
immunoblotting (n=9) and flow cytometry  (n=9) respectively. (E) CLL samples (n=10) were pre-treated 
for 1h with the JAK1/3 inhibitor (CP, Tofacitinib) or the STAT6 inhibitor (AXON; AS1517499) prior to IL-
4 addition for a further 23 hours. sIgM was quantified by flow cytometry. Graphs show mean 
fluorescent intensity (MFI) values. Error bars represent the standard error of the mean (SEM). 
Statistical significance was determined by a paired Wilcoxon matched pairs signed rank test. 
 
Figure 4.  Regulation of anti-IgM and anti-IgD induced calcium flux by IL-4 
CLL samples were treated with IL-4 for 24 hours or left untreated as a control (NA). (A) CLL cells were 
subsequently treated with the JAK1/3 inhibitor (CP) for 1h and then stimulated with soluble αIgM and 
calcium flux assessed by flow cytometry. A representative flow cytometry plot is shown. (B) αIgM 
(n=38) and (C) anti-IgD (n=19) signalling responses were quantified using calcium flux analysis. Graphs 
show fold change in signalling (%responsive cells with IL-4/%responsive cells in the absence of IL-4). 
Statistical significance of differences are shown. (D) Effect of IL-4 titration on anti-IgM-induced calcium 
fluxes as previously described. Statistical significance was determined by paired students T test or 
Wilcoxon matched pairs signed rank test. 
 
Figure 5. IL-4 increases expression of CD79B and the “mature” glycoform of sIgM 
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CLL samples were treated with IL-4 for 24 hours, or left untreated as a control (NA). (A) CD79A and 
CD79B mRNA expression was quantified by Q-PCR (n=9). β2M was used as the house-keeping gene 
and relative expression values were normalized to the untreated cells.  (B) Representative sample 
expressing CD79A and CD79B protein was analysed by immunoblotting (C) summarised CD79B from 
immunoblotting following Image J quantitation (n=26). BCL2 expression was analysed as a loading 
control. (D) The fold change of CD79B expression between the NA control and IL-4 treated cells was 
quantified and represented for U-CLL and M-CLL (n=19). (E) CLL cells were treated with IL-4 and 
assessed by immunoblotting for total levels of -chain (WCL) or surface (SP) -chain. EndoH was used 
to digest the mannosylated µ-chain of IgM (**), whilst the fully glycosylated form (*) was confirmed 
by resistance to EndoH cleavage. (F) Whole cell protein extraction (WCL) or Surface protein (SP) was 
analysed by immunoblotting from CLL samples treated in the presence or absence of IL-4. The protein 
band intensity of mature and immature IgM was quantified using image J (n=12). Statistical 
significance was determined by paired students T test or Wilcoxon matched pairs signed rank test. 
 
Figure 6. Effect of IL-4 on inhibition of sIgM signalling by ibrutinib and idelalisib 
CLL samples were treated with IL-4 for 23 hours or left untreated as a control (NA) and treated then 
with ibrutinib or idelalisib for 1 hour. Anti-IgM-induced calcium fluxes were analysed by flow 
cytometry. (A,B) Representative samples and (C,D) summarised data (n=18) are shown. Black icons 
represent U-CLL and grey icons M-CLL. Graphs show medians and the statistical significance of 
differences between groups. Statistical significance was determined by paired students T test or Mann 
Whitney U test. 
 
Figure 7. The effect of IL-4 on CXCR4 expression 
(A) Histogram showing CXCR4 expression by flow cytometry in a representative CLL sample following 
treatment in the presence or absence of 10ng/ml IL-4 for 24h. Grey histogram, isotype control; solid 
black line, 24h with IL-4; black dotted line, start of the experiment; dashed line, 24h without IL-4.  (B,C) 
Summary of results for all samples analysed at times up to (B) 72 hours (n=9), and at (C) 24 hours 
(n=21). (D) CLL cells were pre-treated with or without the indicated cytokines for 24h and CXCR4 
expression (n=9) quantified by flow cytometry. (E) CLL cells were pre-treated for 1h with the JAK1/3 
inhibitor (CP [CP-690550, Tofacitinib]) or STAT6 inhibitor (AXON; AS1517499) prior to IL-4 addition and 
CXCR4 quantified by flow cytometry at 24h. (F) CLL samples (n=6) were treated with IL-4 for 24 hours 
and migration to CXCL12 quantified by assessing the number of  CD19+CD5+ CLL cells by flow cytometry 
that passed though the transwell plate. Data are expressed as fold change from NA in the absence of 
IL-4 (n=6). Error bars represent the standard error of the mean (SEM). Statistical significance was 
determined by paired students T test or Wilcoxon matched pairs signed rank test. 
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